Early Treatment Failure in Patients With Relapsed/Refractory Multiple Myeloma Receiving Bispecific T-Cell Engagers: Development and Validation of the CHARGE Prognostic Index

医学 多发性骨髓瘤 内科学 肿瘤科 危险系数 比例危险模型 多元分析 贫血 性能状态 总体生存率 无进展生存期 多元统计 免疫疗法 预后变量 连续变量 达拉图穆马 阶段(地层学)
作者
Saurabh Zanwar,Doris K. Hansen,Oren Pasvolsky,Carlyn Rose C. Tan,Lauren Cole Peres,Utkarsh Goel,Rakesh Popat,Aimaz Afrough,Sireesha Asoori,Masooma Shifa Rana,Mrugakshi Dave,Andrew Jay Portuguese,Efstathios Kastritis,James A. Davis,Joaquín Martínez‐López,Douglas Weston Sborov,Jana Mihályová,Susan Bal,Murali Janakiram,Darren Pan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:: JCO2601039-JCO2601039
标识
DOI:10.1200/jco-26-01039
摘要

Purpose Outcomes with bispecific T-cell engagers (TCEs) in relapsed/refractory multiple myeloma (RRMM) are heterogeneous. A practical tool to guide prognosis is needed. We developed a model integrating clinical, biological, and treatment-related variables to predict progression-free survival (PFS) in patients receiving B-cell maturation antigen (BCMA)- or G-protein–coupled receptor class 5 member D-directed TCEs. Methods We evaluated outcomes of 577 BCMA-directed and 366 talquetamab treatments across 15 US Multiple Myeloma Immunotherapy Consortium centers. Variables significantly associated with inferior PFS in a multivariate Cox model were incorporated into a prognostic score and validated in an independent multicenter International Myeloma Foundation cohort. Results With a median follow-up of 8.4 months, the median PFS was 6.4 months (7.0 months for BCMA TCE; 6.1 months for talquetamab); 92% of patients were triple-class-refractory. Six variables significantly associated with inferior PFS—high-risk cytogenetic abnormalities (HRCAs) [del(17p) or ≥2 HRCAs], hyperferritinemia (≥600 ng/mL), anemia (hemoglobin <9 g/dL), early relapse (<18 months from frontline therapy), general performance status (Eastern Cooperative Oncology Group Performance Status ≥2), and exposure to prior BCMA-directed therapy—were combined to form the CHARGE index, stratifying patients into three risk groups. The median PFS was 21.8 months (95% CI, 11.7 to not reached), 7.1 months (95% CI, 6.1 to 10.1), and 1.6 months (95% CI, 1.2 to 2.5) in the low-, intermediate-, and high-risk groups, respectively; hazard ratios (HRs) were 2.0 (95% CI, 1.5 to 2.7) and 4.8 (95% CI, 3.5 to 6.7) for intermediate- and high-risk versus low-risk groups. External validation (n = 173) showed that the median PFS was not reached, 7.0 months, and 3.0 months, with corresponding HRs of 2.9 (95% CI, 1.7 to 4.9) and 4.8 (95% CI, 2.6 to 8.7). Conclusion The CHARGE index provides a simplified and externally validated framework for predicting treatment outcomes in patients with RRMM receiving TCEs.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dde发布了新的文献求助10
刚刚
十一发布了新的文献求助10
1秒前
小马甲的应助被ning采纳,获得10
1秒前
Yannn完成签到,获得积分10
1秒前
苹果思天发布了新的文献求助10
2秒前
郑一鸣完成签到,获得积分10
2秒前
顺心的宛海完成签到,获得积分10
2秒前
喜洋洋完成签到 ,获得积分10
2秒前
2秒前
2秒前
3秒前
852的应助被刘小芬采纳,获得10
4秒前
4秒前
5秒前
暮色将至完成签到,获得积分20
5秒前
咖喱爆炒鱼蛋完成签到,获得积分10
5秒前
情怀的应助被开放的水壶采纳,获得10
5秒前
科研蛀虫完成签到,获得积分10
6秒前
huangyuhang完成签到,获得积分10
6秒前
RC完成签到 ,获得积分10
6秒前
苹果思天发布了新的文献求助10
7秒前
Jasper的应助被英勇啤酒人采纳,获得20
7秒前
7秒前
7秒前
Zephyrine完成签到 ,获得积分10
8秒前
星辰大海的应助被是寄竹吖采纳,获得10
8秒前
苹果思天发布了新的文献求助10
9秒前
十八与雨发布了新的文献求助50
10秒前
10秒前
苹果思天发布了新的文献求助10
11秒前
12秒前
小情绪发布了新的文献求助10
12秒前
大知闲闲发布了新的文献求助10
13秒前
苹果思天发布了新的文献求助10
14秒前
乐乐的应助被典雅的羿采纳,获得10
14秒前
dde发布了新的文献求助10
15秒前
15秒前
包包糖在摸鱼完成签到 ,获得积分10
16秒前
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582